Total synthesis of the antifungal dilactones UK-2A and UK-3A: The determination of their relative and absolute configurations, analog synthesis and antifungal activities

Tetrahedron

Volumn 54, Issue 42, 1998, Pages 12745-12774

  Shimano, Masanao ^a   Kamei, Noriyuki ^a   Shibata, Tetsuo ^a   Inoguchi, Kiyoshi ^a   Itoh, Nobuko ^a   Ikari, Takashi ^a   Senda, Hisato ^a  

^a KAKEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antifungals; Asymmetric synthesis; Medium ring heterocycles; Mitsunobu reactions

Indexed keywords

ANTIFUNGAL AGENT; CITRININ; LACTONE DERIVATIVE; UK 2A; UK 3A; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CYTOTOXICITY; DRUG DEGRADATION; DRUG DETERMINATION; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; MYCOSIS; NONHUMAN; PRIORITY JOURNAL;

FUNGI; STAPHYLOCOCCUS PHAGE 3A;

EID: 0032532259     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(98)00777-7     Document Type: Article

References (46)

1. 1. Rodriguez, M. J.; Hitchcock, S. Exp. Opin. Ther. Patents 1997, 7, 829.
2. 2. Georgopapadakou, N. H.; Walsh, T. J. Antimicrob. Agents Chemother. 1996, 40, 279.
3. 3. Fernandes, P. B., Editor. New approaches for antifungal drugs. Boston: Birkhäuser, 1992, 1.
4. 4. Perfect, J. R. Antimicrob. Agents Chemother. 1996, 40, 1577.
5. 5. a) Ueki, M.; Abe, K.; Hanafi, M.; Shibata, K.; Tanaka, T.; Taniguchi, M. J. Antibiot. 1996, 49, 639.
6. b) Hanafi, M.; Shibata, K.; Ueki, M.; Taniguchi, M. J. Antibiot. 1996, 49, 1226.
7. c) Taniguchi, M.; Shibata, K.; Abe, K.; Kodama, R.; Uotani, K.; Oonishi, Y. Jpn. Patent 1995, 7-233165.
8. 5b
9. 7. a) Liu, W.; van Tamelen, E. E.; Strong, F. M. J. Am. Chem. Soc. 1960, 82, 1652.
10. b) Kinoshita, M.; Aburaki, S.; Umezawa, S. J. Antibiot. 1972, 25, 373.
11. 8. Barrow, C. J.; Oleynek, J. J.; Marinelli, V.; Sun, H. H.; Kaplita, P.; Sedlock, D. M.; Gillum, A. M.; Chadwick, C. C; Cooper, R. J. Antibiot. 1997, 50, 729.
12. 9. a) Dickie, J. P.; Loomans, M. E.; Farley, T. M.; Strong, F. M. J. Med. Chem. 1963, 6, 424.
13. b) Neft, N.; Farley, T. M. J. Med. Chem. 1971, 14, 1169.
14. c) Selwood, D. L.; Livingstone, D. J.; Comley, J. C. W.; O'Dowd, A. B.; Hudson, A. T.; Jackson, P.; Jandu, K. S.; Rose, V. S.; Stables, J. N. J. Med. Chem. 1990, 33, 136.
15. d) Tokutake, N.; Miyoshi, H.; Satoh, T.; Hatano, T.; Iwamura, H. Biochim. Biophys. Acta. 1994, 1185, 271.
16. e) Miyoshi, H.; Tokutake, N.; Imaeda, Y.; Akagi, T.; Iwamura, H. Biochim. Biophys. Acta. 1995, 1229, 149.
17. 10. Ueki, M.; Kusumoto, A.; Hanafi, M.; Shibata, K.; Tanaka, T.; Taniguchi, M. J. Antibiot. 1997, 50, 551.
18. 11. Shimano, M.; Shibata, T.; Kamei, N. Tetrahedron Lett. 1998, 39, 4363.
19. 12. Evans, D. A.; Bartroli, J.; Shih, T. L. J. Am. Chem. Soc. 1981, 103, 2127.
20. 13. Wuts, P. G. M.; Bigelow, S. S. J. Org. Chem. 1983, 48, 3489.
21. 14. All new compounds except volatile compounds were spectroscopically characterized and furnished satisfactory elemental analyses (C, H, N, ± 0.3%) or high-resolution mass spectra. See in the experimental section.
22. 15. Evans, D. A.; Britton, T. C.; Ellma, J. A. Tetrahedron Lett. 1987, 28, 6141.
23. 16. Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. Bull. Chem. Soc. Jpn. 1979, 52, 1989.
24. 17. Nakajima, N.; Horita, K.; Abe, R.; Yonemitsu, O. Tetrahedron Lett. 1988, 29, 4139.
25. 34 was also examined, but the yield was poor because of the by-product formations.
26. 19. a) Oikawa, Y.; Yoshioka, T.; Yonemitsu, O. Tetrahedron Lett. 1982, 23, 885.
27. b) Oikawa, Y.; Yoshioka, T.; Yonemitsu, O. Tetrahedron Lett. 1982, 23, 889.
28. 20. Hikota, M. Sakurai, Y.; Horita, K.; Yonemitsu, O. Tetrahedron Lett. 1990, 31, 6367.
29. 21. Mitsunobu O. Synthesis 1981, 1.
30. 8 methyl group. See: a) Kinoshita, M.; Wada, M.; Aburagi, S.; Umezawa, S. J. Antibiot. 1971, 24, 724.
31. b) Kinoshita, M.; Aburagi, S.; Wada, M.; Umezawa, S. Bull. Chem. Soc. Jpn. 1973, 46, 1279.
32. c) Aburagi, S.; Kinoshita, M. Bull. Chem. Soc. Jpn. 1979, 52, 198.
33. d) Wasserman, H. H.; Gambale, R. J. J. Am. Chem. Soc. 1985, 107, 1423.
34. 23. Trécourt, F.; Mallet, M.; Mongin, O.; Gervais, B.; Quéguiner, G. Tetrahedron 1993, 49, 8373.
35. 24. Winkle, M. R.; Ronald, R. C. J. Org. Chem. 1982, 47, 2101.
36. 25. 4-lodo-3-methoxymethoxypyridine was also prepared with 1,2-diiodo-1,1,2,2-tetrafluoroethane, but the next methoxy replacement was not as good as the case of 4-bromo-3-methoxymethoxypyridine because of the reductive deiodination by-reaction resulting in 3-methoxymethoxypyridine. It should also be noted that 4-bromo-3-methoxymethoxypyridine was much faster to react to NaOMe than 4-iodo-3-methoxymethoxypyridine, although the reason still remains unclear.
37. 26. Structure of UK-2A is depicted with the absolute stereochemistry found in our synthetic UK-2A.
38. 1H NMR of the synthesized γ-lactone 24 was different from the reported one. The coupling pattern of each signal in our γ-lactone 24 was very similar to the reported γ-lactone 24, however, the chemical shifts of some signals were not in accordance with those of the corresponding signals of the reported γ-lactone 24. Since γ-lactone 25 synthesized in our hands was identical with the reported γ-lactone 25, our γ-lactone 24 should be identical with the reported γ-lactone 24.
39. 28. Every candidate was calculated as the protonated form at the nitrogen in the pyridine ring.
40. 29. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. J. Comput. Chem. 1983, 4, 187.
41. 30. a) Perez, J. J.; Villar, H. O.; Loew, G. H. J. Comp. Aided Molec. Design. 1992, 6, 175.
42. b) Centeno, N. B.; Perez, J. J. Chem. Phys. Lett. 1995, 232, 374.
43. 31. Though we have postulated it would be reasonable that the enolization process started from the most stable conformer of each substrate, there might be a possibility that the transformation occurred from the less stable conformer of the starting substrate to the less stable one of the terminal product.
44. 10 because of the small amount of natural UK-3A. In the private communication from Prof. M. Taniguchi and Dr. O. Sakanaka, they were reported as δ 3.08 ppm and δ 65.1 ppm, respectively.
45. 4 segment in the nine-membered dilactone were both chiral, we believe that the optical purity of our γ-lactone 25 is excellent.
46. 34. Evans, D. A.; Ennis, M. D.; Mathre, D. J. J. Am. Chem. Soc. 1982, 104, 1737.